Penetration of meropenem into epithelial lining fluid of patients with ventilator-associated pneumonia
about
Individualised antibiotic dosing for patients who are critically ill: challenges and potential solutions.Comparison of intrapulmonary and systemic pharmacokinetics of colistin methanesulfonate (CMS) and colistin after aerosol delivery and intravenous administration of CMS in critically ill patients.Interaction of drug- and granulocyte-mediated killing of Pseudomonas aeruginosa in a murine pneumonia model.Optimization of aminoglycoside therapy.Meropenem penetration into epithelial lining fluid in mice and humans and delineation of exposure targets.Population pharmacokinetics and Monte Carlo dosing simulations of meropenem during the early phase of severe sepsis and septic shock in critically ill patients in intensive care unitsCombination treatment with meropenem plus levofloxacin is synergistic against Pseudomonas aeruginosa infection in a murine model of pneumoniaPopulation Pharmacokinetics and Target Attainment of Meropenem in Plasma and Tissue of Morbidly Obese Patients after Laparoscopic Intraperitoneal Surgery.Pharmacokinetic and Pharmacodynamic Principles of Anti-infective Dosing.Meropenem-RPX7009 Concentrations in Plasma, Epithelial Lining Fluid, and Alveolar Macrophages of Healthy Adult Subjects.Impact of meropenem in combination with tobramycin in a murine model of Pseudomonas aeruginosa pneumonia.Ceftolozane/tazobactam pharmacokinetic/pharmacodynamic-derived dose justification for phase 3 studies in patients with nosocomial pneumonia.Changes in ceftriaxone pharmacokinetics/pharmacodynamics during the early phase of sepsis: a prospective, experimental study in the rat.Efficacies of ceftazidime-avibactam and ceftazidime against Pseudomonas aeruginosa in a murine lung infection model.Penetration of anti-infective agents into pulmonary epithelial lining fluid: focus on antibacterial agents.Year in review 2010: Critical Care--Infection.Prolonged infusions of β-lactam antibiotics: implication for antimicrobial stewardship.Antibacterial activity of human simulated epithelial lining fluid concentrations of amikacin inhale alone and in combination with meropenem against Acinetobacter baumannii.Carbapenem susceptibility breakpoints, clinical implications with the moving target.The role of infection models and PK/PD modelling for optimising care of critically ill patients with severe infections.Amikacin in Critically Ill Patients: A Review of Population Pharmacokinetic Studies.[Therapeutic drug monitoring and individual dosing of antibiotics during sepsis : Modern or just "trendy"?]Antibacterial activity of achievable epithelial lining fluid exposures of Amikacin Inhale with or without meropenem.Determination of meropenem penetration into the lung from Sparse data.Intrapulmonary Pharmacokinetics of Relebactam, a Novel β-lactamase Inhibitor, Dosed in Combination with Imipenem/Cilastatin in Healthy Subjects.[Bacterial sepsis : Diagnostics and calculated antibiotic therapy].Pharmacokinetic modelling of serum and bronchial concentrations for clarithromycin and telithromycin, and site-specific pharmacodynamic simulation for their dosages.Phase 1 study assessing the steady-state concentration of ceftazidime and avibactam in plasma and epithelial lining fluid following two dosing regimens.Pharmacokinetics of continuous-infusion meropenem in a pediatric patient receiving extracorporeal life support.
P2860
Q34274190-D2063538-8D6D-4455-BE19-A927628EAA79Q34597749-82470C59-2795-49DC-A0A3-903B92C2062EQ34736543-B57E0F3F-72AA-4AF0-A255-4A4DF2D44668Q35005127-99EB6372-B853-44B1-B24A-BA8DBA71064AQ35065847-F7F0DC87-9188-4FFA-B05B-E367972E1B66Q35607715-5E961AD5-7774-4BAC-AC03-BA1E7C9D20DBQ35661926-1BDC5C97-E220-4F17-AFCD-783B8E624A8CQ36076101-2EDCF244-10D2-418D-9810-13328C36B5A7Q36083619-E764F3FC-ACC3-4763-B3C4-02DB9ABDE263Q36290773-3DC08576-F4FD-4481-8506-C36AFF104F70Q37026595-C498BA12-63B5-4B50-ADCA-62567AE29646Q37308807-71D51F0F-9173-48FC-8CD8-4FCC20A8DE0DQ37416986-0D01CEF4-702F-467D-8D45-EEC6F91D2169Q37643614-53A6E720-AF0F-4201-AF21-6F367C712A67Q37927017-EEC98168-49F1-438B-9C10-E16752291741Q37966018-A6F19D5B-43F2-433D-9806-0720AD12B098Q38073197-E467F4D0-D49D-4BD6-8E42-CE52C46E3293Q38652103-7A9CD070-66A4-42FF-B911-AE920FD638D6Q38751264-D0A20EBB-B49D-47E5-B066-6DD13A204A11Q38837353-F0075B49-A85B-4217-8E79-FAD724ECD46AQ38850670-37E8893B-2B85-4BE0-AC8A-A6E2FF6E3F25Q40541397-F70FF703-4C22-47D2-B983-86FDF83E241CQ40913492-E04C3094-BEBE-4A30-BE6B-975927EAC529Q43005046-E63514A4-919D-4F02-BCBB-D2A5F4300170Q47195583-0C9E9ED1-D623-4FC0-9D99-A9BE4642AF84Q49589601-21C13701-227B-4B04-B7C7-00AFCAEC48FCQ51100124-74AA64B0-702A-4AD3-8466-5A0FC13BEC18Q51616538-B96F7946-6736-4780-8E46-74758902F588Q51702479-917360BD-DD27-4A18-A03E-4C74AC92B650
P2860
Penetration of meropenem into epithelial lining fluid of patients with ventilator-associated pneumonia
description
2011 nî lūn-bûn
@nan
2011 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Penetration of meropenem into ...... entilator-associated pneumonia
@ast
Penetration of meropenem into ...... entilator-associated pneumonia
@en
Penetration of meropenem into ...... entilator-associated pneumonia
@nl
type
label
Penetration of meropenem into ...... entilator-associated pneumonia
@ast
Penetration of meropenem into ...... entilator-associated pneumonia
@en
Penetration of meropenem into ...... entilator-associated pneumonia
@nl
prefLabel
Penetration of meropenem into ...... entilator-associated pneumonia
@ast
Penetration of meropenem into ...... entilator-associated pneumonia
@en
Penetration of meropenem into ...... entilator-associated pneumonia
@nl
P2093
P2860
P921
P356
P1476
Penetration of meropenem into ...... entilator-associated pneumonia
@en
P2093
P2860
P304
P356
10.1128/AAC.01330-10
P407
P577
2011-02-07T00:00:00Z